High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.

Huihui ZhangNinghan ZhangRong WangTingting ShaoYuan FengYao YaoQingyun WuShengyun ZhuJiang CaoHuanxin ZhangZhenyu LiXuejiao LiuMingshan NiuKailin Xu

Published in: Journal of translational medicine (2019)

In summary, miR-363 expression may help identify patients in need of strategies to select the optimal therapy between chemotherapeutic and allo-HCST regimens. AML patients with high miR-363 expression may be highly recommended for early allo-HSCT regimen.

Keyphrases

poor prognosis
long non coding rna
cell proliferation
end stage renal disease
long noncoding rna
ejection fraction
chronic kidney disease
acute myeloid leukemia
prognostic factors
stem cells
peritoneal dialysis
acute lymphoblastic leukemia
replacement therapy